skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 4,862  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Show only
Refined by: subject: Middle Aged remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study
Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study
Material Type:
Article 		Add to My Research

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

BMJ (Online), 2021-03, Vol.372, p.n579-n579 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ. ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ. BMJ This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ. 2021 BMJ ;ISSN: 1756-1833 ;ISSN: 0959-8138 ;EISSN: 1756-1833 ;DOI: 10.1136/bmj.n579 ;PMID: 33687922

Full text available

Citations Cited by
2
Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China
Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China
Material Type:
Article 		Add to My Research

Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China

Journal of Medical Virology, 2020-04, Vol.92 (4) [Peer Reviewed Journal]

2020. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://novel-coronavirus.onlinelibrary.wiley.com ;DOI: 10.1002/jmv.25689

Digital Resources/Online E-Resources

Citations Cited by
3
Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016
Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016
Material Type:
Article 		Add to My Research

Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016

The New England journal of medicine, 2018-12, Vol.379 (25), p.2429-2437 [Peer Reviewed Journal]

Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1804492 ;PMID: 30575491

Full text available

Citations Cited by
4
Estimates of the severity of coronavirus disease 2019: a model-based analysis
Estimates of the severity of coronavirus disease 2019: a model-based analysis
Material Type:
Article 		Add to My Research

Estimates of the severity of coronavirus disease 2019: a model-based analysis

The Lancet Infectious Diseases, 2020-06, Vol.20 (6), p.669-677 [Peer Reviewed Journal]

2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at http://creativecommons.org/licenses/by/4.0 ;2020. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2020 ;ISSN: 1473-3099 ;EISSN: 1474-4457 ;DOI: 10.1016/S1473-3099(20)30243-7 ;PMID: 32240634

Digital Resources/Online E-Resources

Citations Cited by
5
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
Material Type:
Article 		Add to My Research

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

New England Journal of Medicine, 2020-11, Vol.383 (21), p.2030-2040 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2020 Massachusetts Medical Society. All rights reserved. 2020 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2022926 ;PMID: 33031652

Digital Resources/Online E-Resources

Citations Cited by
6
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
Material Type:
Article 		Add to My Research

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

The Lancet (British edition), 2023-01, Vol.401 (10373), p.281-293 [Peer Reviewed Journal]

2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2023. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(22)02597-1 ;PMID: 36566761

Full text available

Citations Cited by
7
Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
Material Type:
Article 		Add to My Research

Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

The Lancet (British edition), 2019-05, Vol.393 (10184), p.1958-1972 [Peer Reviewed Journal]

2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2019. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2019 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(19)30041-8 ;PMID: 30954305

Full text available

Citations Cited by
8
Humoral Immune Response to SARS-CoV-2 in Iceland
Humoral Immune Response to SARS-CoV-2 in Iceland
Material Type:
Article 		Add to My Research

Humoral Immune Response to SARS-CoV-2 in Iceland

New England Journal of Medicine, 2020-10, Vol.383 (18), p.1724-1734 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2020 Massachusetts Medical Society. All rights reserved. 2020 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2026116 ;PMID: 32871063

Digital Resources/Online E-Resources

Citations Cited by
9
Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
Material Type:
Article 		Add to My Research

Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

Lancet neurology, 2019-05, Vol.18 (5), p.439-458 [Peer Reviewed Journal]

2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2019. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. ;2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2019 ;ISSN: 1474-4422 ;ISSN: 1474-4465 ;EISSN: 1474-4465 ;DOI: 10.1016/S1474-4422(19)30034-1 ;PMID: 30871944

Full text available

Citations Cited by
10
Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study
Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study
Material Type:
Article 		Add to My Research

Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study

The Lancet Oncology, 2020-08, Vol.21 (8), p.1035-1044 [Peer Reviewed Journal]

2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.elsevier.com/legal/elsevier-website-terms-and-conditions ;2020. Elsevier Ltd ;2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(20)30392-2 ;PMID: 32702311

Digital Resources/Online E-Resources

Citations Cited by
11
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Material Type:
Article 		Add to My Research

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

The Lancet (British edition), 2018-03, Vol.391 (10126), p.1163-1173 [Peer Reviewed Journal]

2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 24, 2018 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(18)30207-1 ;PMID: 29433850

Full text available

Citations Cited by
12
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Material Type:
Article 		Add to My Research

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

The Lancet (British edition), 2021-07, Vol.398 (10294), p.27-40 [Peer Reviewed Journal]

2021 Elsevier Ltd ;Copyright © 2021 Elsevier Ltd. All rights reserved. ;2021. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)00797-2 ;PMID: 34102137

Full text available

Citations Cited by
13
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Material Type:
Article 		Add to My Research

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

The Lancet (British edition), 2021-05, Vol.397 (10285), p.1637-1645 [Peer Reviewed Journal]

2021 Published by Elsevier Ltd. All rights reserved. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2021 Published by Elsevier Ltd. All rights reserved. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2021. Published by Elsevier Ltd. All rights reserved. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 Published by Elsevier Ltd. All rights reserved. This is an Open Access article under the CC BY 4.0 license 2021 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)00676-0 ;PMID: 33933206

Full text available

Citations Cited by
14
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
Material Type:
Article 		Add to My Research

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

The Lancet (British edition), 2021-05, Vol.397 (10287), p.1819-1829 [Peer Reviewed Journal]

2021 Elsevier Ltd ;Copyright © 2021 Elsevier Ltd. All rights reserved. ;2021. Elsevier Ltd ;2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)00947-8 ;PMID: 33964222

Full text available

Citations Cited by
15
Variation in COVID-19 Hospitalizations and Deaths Across New York City Boroughs
Variation in COVID-19 Hospitalizations and Deaths Across New York City Boroughs
Material Type:
Article 		Add to My Research

Variation in COVID-19 Hospitalizations and Deaths Across New York City Boroughs

JAMA, 2020-06 [Peer Reviewed Journal]

2020. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://jamanetwork.com/journals/jama/pages/coronavirus-alert . ;DOI: 10.1001/jama.2020.7197

Digital Resources/Online E-Resources

Citations Cited by
16
Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy
Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy
Material Type:
Article 		Add to My Research

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

JAMA, 2020-05, Vol.323 (18), p.1775 [Peer Reviewed Journal]

2020. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://jamanetwork.com/journals/jama/pages/coronavirus-alert . ;DOI: 10.1001/jama.2020.4683

Digital Resources/Online E-Resources

Citations Cited by
17
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
Material Type:
Article 		Add to My Research

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

The Lancet Oncology, 2020-10, Vol.21 (10), p.1309-1316 [Peer Reviewed Journal]

2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.elsevier.com/legal/elsevier-website-terms-and-conditions ;2020. Elsevier Ltd ;2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(20)30442-3 ;PMID: 32853557

Digital Resources/Online E-Resources

Citations Cited by
18
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Material Type:
Article 		Add to My Research

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

The Lancet (British edition), 2021-02, Vol.397 (10274), p.605-612 [Peer Reviewed Journal]

2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2021. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2021 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)00149-5 ;PMID: 33545096

Full text available

Citations Cited by
19
COVID-19 Cases and Deaths in Federal and State Prisons
COVID-19 Cases and Deaths in Federal and State Prisons
Material Type:
Article 		Add to My Research

COVID-19 Cases and Deaths in Federal and State Prisons

JAMA, 2020-08, Vol.324 (6), p.602 [Peer Reviewed Journal]

2020. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://jamanetwork.com/journals/jama/pages/coronavirus-alert . ;DOI: 10.1001/jama.2020.12528

Digital Resources/Online E-Resources

Citations Cited by
20
Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study
Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study
Material Type:
Article 		Add to My Research

Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study

The Lancet infectious diseases, 2021-06, Vol.21 (6), p.793-802 [Peer Reviewed Journal]

2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license ;Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2021. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. This work is published under http://creativecommons.org/licenses/by-nc-nd/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license 2021 ;ISSN: 1473-3099 ;EISSN: 1474-4457 ;DOI: 10.1016/S1473-3099(21)00143-2 ;PMID: 33743847

Full text available

Citations Cited by

Results 1 - 20 of 4,862  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (4,719)

Refine My Results

Creation Date 

From To
Refine
  1. Before 1980  (14)
  2. 1980 To 1990  (45)
  3. 1991 To 2000  (384)
  4. 2001 To 2011  (995)
  5. After 2011  (3,425)
  6. More options open sub menu

Resource Type 

  1. Articles  (4,856)
  2. magazinearticle  (6)
  3. More options open sub menu

Subject 

  1. Humans  (4,861)
  2. Science & Technology  (4,566)
  3. Fatalities  (4,499)
  4. Male  (4,216)
  5. Female  (4,208)
  6. Adult  (3,925)
  7. Life Sciences & Biomedicine  (3,774)
  8. Aged  (3,224)
  9. Mortality  (2,477)
  10. Adolescent  (2,054)
  11. Young Adult  (1,766)
  12. Risk Factors  (1,589)
  13. Aged, 80 And Over  (1,450)
  14. Patients  (1,193)
  15. Child  (1,116)
  16. Public, Environmental & Occupational Health  (1,074)
  17. Public Health  (1,007)
  18. Epidemiology  (999)
  19. Age  (944)
  20. More options open sub menu

Language 

  1. Japanese  (682)
  2. Portuguese  (19)
  3. Norwegian  (13)
  4. Spanish  (4)
  5. French  (3)
  6. German  (2)
  7. Chinese  (2)
  8. Russian  (1)
  9. Italian  (1)
  10. Catalan  (1)
  11. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait